Reza Fathi
Chief Tech/Sci/R&D Officer bei REDHILL BIOPHARMA LTD.
Vermögen: 95 442 $ am 31.03.2024
Profil
Reza Fathi is a Senior Vice President-Research & Development at RedHill Biopharma Ltd.
He previously worked as a Director-Research Operations at XTL Biopharmaceuticals Ltd., Director-Research & Operations at VivoQuest, Inc., Head-Discovery Group at PharmaGenics, Inc., and Manager-Chemical Biology Research at Harvard Medical School.
Dr. Fathi holds a doctorate degree from Rutgers State University of New Jersey and an undergraduate degree from Texas Tech University.
Bekannte Unternehmensbeteiligungen
| Unternehmen | Datum | Anzahl der Aktien | Bewertung | Datum der Bewertung |
|---|---|---|---|---|
REDHILL BIOPHARMA LTD.
0,02% | 04.04.2024 | 1 800 800 ( 0,02% ) | 95 442 $ | 31.03.2024 |
Aktive Positionen von Reza Fathi
| Unternehmen | Position | Beginn |
|---|---|---|
| REDHILL BIOPHARMA LTD. | Chief Tech/Sci/R&D Officer | 01.05.2010 |
Ehemalige bekannte Positionen von Reza Fathi
| Unternehmen | Position | Ende |
|---|---|---|
| XTL BIOPHARMACEUTICALS LTD. | Chief Tech/Sci/R&D Officer | - |
VivoQuest, Inc.
 VivoQuest, Inc. BiotechnologyHealth Technology VivoQuest, Inc. is engaged into the discovery and development of prescription drugs based on natural compounds derived small molecules. The in-house discovery research program in chemistry and biology aims at establishing and screening unique libraries of natural product-like compounds. VivoQuest's initial therapeutic area is the anti-viral field, including HIV and hepatitis C. VivoQuest is headquartered in Valley Cottage, NY. | Chief Operating Officer | - |
| Harvard Medical School | Corporate Officer/Principal | 01.01.2000 |
PharmaGenics, Inc.
 PharmaGenics, Inc. Miscellaneous Commercial ServicesCommercial Services PharmaGenics, Inc. develops therapeutic products for cancer. The American company was founded by Mike I. Sherman. PharmaGenics was acquired by Genzyme Corp., part of Sanofi from April 08, 2011 on June 18, 1997 for $112 million. | Corporate Officer/Principal | 01.01.1998 |
Ausbildung von Reza Fathi
| Rutgers State University of New Jersey | Doctorate Degree |
| Texas Tech University | Undergraduate Degree |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
| Börsennotierte Unternehmen | 2 |
|---|---|
| XTL BIOPHARMACEUTICALS LTD. | Health Technology |
| REDHILL BIOPHARMA LTD. | Health Technology |
| Private Unternehmen | 2 |
|---|---|
PharmaGenics, Inc.
PharmaGenics, Inc. Miscellaneous Commercial ServicesCommercial Services PharmaGenics, Inc. develops therapeutic products for cancer. The American company was founded by Mike I. Sherman. PharmaGenics was acquired by Genzyme Corp., part of Sanofi from April 08, 2011 on June 18, 1997 for $112 million. | Commercial Services |
VivoQuest, Inc.
VivoQuest, Inc. BiotechnologyHealth Technology VivoQuest, Inc. is engaged into the discovery and development of prescription drugs based on natural compounds derived small molecules. The in-house discovery research program in chemistry and biology aims at establishing and screening unique libraries of natural product-like compounds. VivoQuest's initial therapeutic area is the anti-viral field, including HIV and hepatitis C. VivoQuest is headquartered in Valley Cottage, NY. | Health Technology |
